DGX Stock Analysis: Buy, Sell, or Hold?
DGX - Quest Diagnostics Inc.
$193.58
-1.42 (-0.73%)
▼
5d:
-4.67%
30d:
-0.09%
90d:
-0.86%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 23, 2026
29d
Get Alerted When DGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DGX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: DGX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$272.60
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$169.27
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DGX is currently trading at $193.58, which is considered slightly low relative to its 30-day fair value range of $191.52 to $200.88. The stock's valuation (Forward PE: 16.6) is in line with its historical norms (17.3). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This pessimistic expectation contrasts with the company's recent 15.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DGX is showing sideways momentum. The price is currently testing key support at $191.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $223.44 (+15.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DGX is showing sideways momentum. The price is currently testing key support at $191.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $223.44 (+15.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$191.52 -
$200.88
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($223.44)
Trading Range Analysis
30-Day Trading Range
$191.52 -
$200.88
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$7.42
(3.8%)
Support & Resistance Levels
Support Level
$191.02
Resistance Level
$204.84
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.59
Wall Street Target
$223.44
(+15.4%)
Revenue Growth (YoY)
9.2%
Earnings Growth (YoY)
15.5%
Profit Margin
9.1%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
16.6 vs 17.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$190.87
(-1%)
2-Year Target
$188.20
(-3%)
3-Year Target
$185.56
(-4%)
3-Yr Target (if PE normalizes)
(PE: 17→17)
$193.54
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 8.4%)
$323.53
(+67%)
Base:
(SPY PE: 16.6, Growth: 8.4%)
$246.39
(+27%)
Bear:
(PE: 14.1, Growth: 8.4%)
$209.43
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 21.55 | Current EPS (TTM): $9.05
Bull Case
$276.62
(+43%)
Analyst growth 29.0%, PE expands to 23.7
Base Case
$251.47
(+30%)
Market implied 29.0%, PE stable at 21.6
Bear Case
$132.60
(-32%)
Severe decline -20.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.6 to 17.3
Stabilization Target:
$201.90
(+4.3%)
PE Expansion Potential:
+4.3%
Share & Embed Analysis
Last updated: June 23, 2026 7:30 AM ET
Data refreshes hourly during market hours. Next update: 8:30 AM
Data refreshes hourly during market hours. Next update: 8:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DGX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael E Prevoznik
SELL
3878 shares
2026-03-05
Patrick Plewman
SELL
2855 shares
2026-03-05
Catherine T Doherty
SELL
5558 shares
2026-03-05
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$142 | 56 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 51 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 62 BUY |
Advanced DGX Option Strategies
Professional options setups generated by AI based on today's DGX price and gamma walls.
